Show simple item record

dc.contributor.authorPeña Asensio, Julia 
dc.contributor.authorCalvo Sánchez, Henar
dc.contributor.authorTorralba González de Suso, Miguel 
dc.contributor.authorMiquel Plaza, Joaquín
dc.contributor.authorSanz de Villalobos, Eduardo
dc.contributor.authorLarrubia Marfil, Juan Ramón 
dc.date.accessioned2022-03-07T10:18:42Z
dc.date.available2022-03-07T10:18:42Z
dc.date.issued2021-05-03
dc.identifier.bibliographicCitationCells, 2021, v. 10, n. 3, p. 538-en
dc.identifier.issn2073-4409en
dc.identifier.urihttp://hdl.handle.net/10017/50987
dc.description.abstractHepatitis C virus (HCV)-specific CD8+ T cell response is essential in natural HCV infection control, but it becomes exhausted during persistent infection. Nowadays, chronic HCV infection can be resolved by direct acting anti-viral treatment, but there are still some non-responders that could benefit from CD8+ T cell response restoration. To become fully reactive, T cell needs the complete release of T cell receptor (TCR) signalling but, during exhaustion this is blocked by the PD-1 effect on CD28 triggering. The T cell pool sensitive to PD-1 modulation is the progenitor subset but not the terminally differentiated effector population. Nevertheless, the blockade of PD-1/PD-L1 checkpoint cannot be always enough to restore this pool. This is due to the HCV ability to impair other co-stimulatory mechanisms and metabolic pathways and to induce a pro-apoptotic state besides the TCR signalling impairment. In this sense, gamma-chain receptor cytokines involved in memory generation and maintenance, such as low-level IL-2, IL-7, IL-15, and IL-21, might carry out a positive effect on metabolic reprogramming, apoptosis blockade and restoration of co-stimulatory signalling. This review sheds light on the role of combinatory immunotherapeutic strategies to restore a reactive anti-HCV T cell response based on the mixture of PD-1 blocking plus IL-2/IL-7/IL-15/IL-21 treatment.en
dc.description.sponsorshipMINECOes
dc.description.sponsorshipInstituto de Salud Carlos IIIes
dc.description.sponsorshipEuropean Commissionen
dc.description.sponsorshipGilead Fellowship Programmeen
dc.description.sponsorshipEuropean Regional Development Fund (ERDF)en
dc.format.mimetypeapplication/pdfen
dc.language.isoengen
dc.language.isoengen
dc.rights© 2021 by the authors. Licensee MDPIen
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)en
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectCD8+ T cell responseen
dc.subjectHepatitis C virusen
dc.subjectIL-15en
dc.subjectIL-2en
dc.subjectIL-21en
dc.subjectIL-7en
dc.subjectPD-1en
dc.subjectPD-L1en
dc.subjectExhaustionen
dc.subjectImmune checkpointsen
dc.subjectGamma-chain cytokinesen
dc.titleGamma-Chain Receptor Cytokines & PD-1 Manipulation to Restore HCV-Specific CD8 + T Cell Response during Chronic Hepatitis Cen
dc.typeinfo:eu-repo/semantics/articleen
dc.subject.ecienciaMedicinaes
dc.subject.ecienciaMedicineen
dc.contributor.affiliationUniversidad de Alcalá. Departamento de Medicina y Especialidades Médicases
dc.date.updated2022-03-07T10:15:59Z
dc.type.versioninfo:eu-repo/semantics/publishedVersionen
dc.identifier.doi10.3390/cells10030538
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/ PI19%2F00206/ES/en
dc.relation.projectIDinfo:eu-repo/grantAgreement/Gilead Sciences/ Gilead Fellowship Program in HIV & Hepatitis/ GLD14%2F00217 (JRL)/ES/en
dc.relation.projectIDinfo:eu-repo/grantAgreement/Gilead Sciences/ Gilead Fellowship Program in HIV & Hepatitis/ GLD16%2F00014 (JRL)/ES/en
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessen
dc.identifier.uxxiAR/0000040468
dc.identifier.publicationtitleCellsen
dc.identifier.publicationvolume10
dc.identifier.publicationissue3
dc.identifier.publicationfirstpage538


Files in this item

Thumbnail

This item appears in the following Collection(s)

© 2021 by the authors. Licensee MDPI
Este ítem está sujeto a una licencia Creative Commons.